Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioCorRxBICX +19.05%31 Equity-to-Asset is -6.41 as of Jun. 2026. GuruFocus rates BICX with a GF Score™ of 31/100 and a GF Value™ of $2.13 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 683 Healthcare Providers & Services companies, BioCorRx ranks worse than 98.68% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. BioCorRx's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $-12.23 Mil. BioCorRx's Total Assets for the quarter that ended in Jun. 2026 was $1.91 Mil.
Therefore, BioCorRx's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was -6.41.
The historical rank and industry rank for BioCorRx's Equity-to-Asset or its related term are showing as below:
BICX'
s Equity-to-Asset Range Over the Past 10 Years
Min: -33.88 Med: -7.31 Max: 0.02
Current: -6.41
During the past 13 years, the highest Equity to Asset Ratio of BioCorRx was 0.02. The lowest was -33.88. And the median was -7.31.
BICX's Equity-to-Asset is ranked worse than 98.68% of 683
companies
in the Healthcare Providers & Services industry
Industry Median: 0.49
vs BICX: -6.41
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
BioCorRx Equity-to-Asset Related Terms
BioCorRx Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for BioCorRx's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BICX vs VLXC, XCRT, RHEP: Equity-to-Asset Comparison
For the Medical Care Facilities subindustry, BioCorRx's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioCorRx Equity-to-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, BioCorRx's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where BioCorRx's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
BioCorRx's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioCorRx (BICX) has a Equity-to-Asset of -6.41 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on BioCorRx and its competitors. According to the industry distribution chart, BioCorRx ranks #674 out of 683 companies in the Healthcare Providers & Services industry, placing it in the top 98.7%.
Is BioCorRx's Equity-to-Asset too high?
BioCorRx's current Equity-to-Asset is -6.41. Based on the distribution chart, BioCorRx ranks #674 out of 683 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, BioCorRx has a GF Score™ of 31/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioCorRx's Equity-to-Asset compare to VLXC and XCRT?
According to the Healthcare Providers & Services industry distribution chart, BioCorRx ranks #674 out of 683 companies for Equity-to-Asset. This places BioCorRx in the lower half of its industry. The industry median Equity-to-Asset is 0.49. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Healthcare Providers & Services company?
The median Equity-to-Asset among Healthcare Providers & Services companies is 0.49, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on BioCorRx and its competitors. For the Healthcare Providers & Services industry, the median Equity-to-Asset is 0.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioCorRx's current Equity-to-Asset is -6.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioCorRx stock overvalued right now?
Based on GuruFocus' analysis, BioCorRx (BICX) is currently considered Possible Value Trap. The stock's GF Value™ is $2.13, compared to a current price of $0.25 — trading 88.3% below its estimated fair value. The current Equity-to-Asset is -6.41. BioCorRx's overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For BioCorRx (BICX), the current Equity-to-Asset is -6.41 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioCorRx (BICX) Overvalued in 2026?
Based on GuruFocus' analysis, BioCorRx stock appears to be undervalued.
The current stock price of $0.25 is trading 88.3% below its estimated GF Value™ of $2.13.
GuruFocus considers BioCorRx to be Possible Value Trap.
Key valuation signals for BICX:
Equity-to-Asset: -6.41
GF Value™: $2.13 vs. price of $0.25 (88.3% below fair value)
No single metric tells the full story. See the BICX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioCorRx Inc through its subsidiaries, develops and provides addiction treatment solutions, offering an approach to the treatment of substance use and other related disorders. The company makes the Beat Addiction Recovery Program and UnCraveRx Weight Loss Management Program available to healthcare providers to utilize when the healthcare provider determines it is medically appropriate and indicated for their patients. Its products include BICX102 and BICX104. It operates in a single segment.
31GF Score
Get the complete analysis for BICX
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BICX has been successfully added to your 
